Recordati buys Sanofi’s drug for autoimmune disease for $825 million
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.
Drugs
Health
Pharma
Climate
Drugs
Pharma
Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.
Drugs
Health
Pharma
EMA starts review of medicines to treat hair loss, prostate enlargement
The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.
Drugs
Health
Pharma
UK scientists receive funding to develop world’s first ovarian cancer vaccine
HQ Team October 4, 2024: Researchers at the University of Oxford have received £600,000 (€719,960) from Cancer Research UK to fund their project.
Drugs
Health
Pharma
AstraZeneca’s experimental blood cancer drug gets US priority review
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.
Drugs
Health
Pharma
Gilead signs six global pacts to make, sell generic HIV preventive drug
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
Drugs
Health
Pharma
WHO reports new case of MERS-CoV in Saudi Arabia, risk ‘moderate’
The WHO has been notified of a human case of Middle East Respiratory coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia.
Drugs
Health
Pharma
Amplifica’s human trial medicine for hair growth shows 15% more efficacy
Amplifica Holdings Group Inc.’s first-in-human trial of an injectable medicine for treating hair loss has shown a more than 15% increase in non-vellus.
Drugs
Health
Pharma
Brazil becomes 20th WHO-validated nation to eliminate lymphatic filariasis
Brazil became the 20th country in the world that has been validated by WHO to have eliminated lymphatic filariasis as a public health.
Drugs
Health
Pharma
J&J to build $2b facility in North Carolina to make future products
HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.